TR199600930A2 - Kristal yapida (R)-(-)-2-{N-£4-(1,1-dioksido-3-okzo-2, 3-dihidrobenzizotiazol-2-il)-butil|- aminometil}-kroman hidroklorür. - Google Patents

Kristal yapida (R)-(-)-2-{N-£4-(1,1-dioksido-3-okzo-2, 3-dihidrobenzizotiazol-2-il)-butil|- aminometil}-kroman hidroklorür.

Info

Publication number
TR199600930A2
TR199600930A2 TR96/00930A TR9600930A TR199600930A2 TR 199600930 A2 TR199600930 A2 TR 199600930A2 TR 96/00930 A TR96/00930 A TR 96/00930A TR 9600930 A TR9600930 A TR 9600930A TR 199600930 A2 TR199600930 A2 TR 199600930A2
Authority
TR
Turkey
Prior art keywords
dihydrobenzisothiazol
dioxido
aminomethyl
oxo
butyl
Prior art date
Application number
TR96/00930A
Other languages
English (en)
Inventor
Dr Alfons Grunenberg
Dr Oliver Brehm
Dr Michael Conrad
Dr Dietrich Seidel
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of TR199600930A2 publication Critical patent/TR199600930A2/tr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
TR96/00930A 1995-11-22 1996-11-22 Kristal yapida (R)-(-)-2-{N-£4-(1,1-dioksido-3-okzo-2, 3-dihidrobenzizotiazol-2-il)-butil|- aminometil}-kroman hidroklorür. TR199600930A2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19543478A DE19543478A1 (de) 1995-11-22 1995-11-22 Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman

Publications (1)

Publication Number Publication Date
TR199600930A2 true TR199600930A2 (tr) 1997-06-21

Family

ID=7778081

Family Applications (1)

Application Number Title Priority Date Filing Date
TR96/00930A TR199600930A2 (tr) 1995-11-22 1996-11-22 Kristal yapida (R)-(-)-2-{N-£4-(1,1-dioksido-3-okzo-2, 3-dihidrobenzizotiazol-2-il)-butil|- aminometil}-kroman hidroklorür.

Country Status (32)

Country Link
US (1) US5830908A (tr)
EP (1) EP0775704B1 (tr)
JP (1) JPH09143180A (tr)
KR (1) KR970027079A (tr)
CN (1) CN1086703C (tr)
AR (1) AR004961A1 (tr)
AT (1) ATE201872T1 (tr)
AU (1) AU712922B2 (tr)
BR (1) BR9605646A (tr)
CA (1) CA2190700A1 (tr)
CZ (1) CZ289730B6 (tr)
DE (2) DE19543478A1 (tr)
DK (1) DK0775704T3 (tr)
EE (1) EE9600183A (tr)
ES (1) ES2159342T3 (tr)
GR (1) GR3036505T3 (tr)
HU (1) HUP9603237A3 (tr)
IL (1) IL119647A (tr)
MX (1) MX9605741A (tr)
MY (1) MY132473A (tr)
NO (1) NO307340B1 (tr)
NZ (1) NZ299780A (tr)
PL (1) PL317090A1 (tr)
PT (1) PT775704E (tr)
RU (1) RU2181723C2 (tr)
SG (1) SG44989A1 (tr)
SI (1) SI0775704T1 (tr)
SK (1) SK150096A3 (tr)
TR (1) TR199600930A2 (tr)
TW (1) TW449595B (tr)
UA (1) UA45338C2 (tr)
ZA (1) ZA969753B (tr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2009024542A2 (en) * 2007-08-17 2009-02-26 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
NZ604091A (en) * 2008-08-15 2014-08-29 Boehringer Ingelheim Int Purin derivatives for use in the treatment of fab-related diseases
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sirs及び/又は敗血症の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748182A (en) * 1986-03-05 1988-05-31 Merrell Dow Pharmaceuticals Inc. Aromatic 2-aminoalkyl-1,2-benzoisothiazol-3(2H)one-1,1-dioxide derivatives and their use as anti-hypertensive and anxiolytic agents
US5300523A (en) * 1988-07-28 1994-04-05 Bayer Aktiengesellschaft Substituted aminomethyltetralins and their heterocyclic analogues
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE4138756A1 (de) * 1991-11-26 1993-05-27 Troponwerke Gmbh & Co Kg Kombination mit neuroprotektiver wirkung

Also Published As

Publication number Publication date
PL317090A1 (en) 1997-05-26
DK0775704T3 (da) 2001-07-23
AU712922B2 (en) 1999-11-18
NO964950D0 (no) 1996-11-21
SI0775704T1 (en) 2001-08-31
DE19543478A1 (de) 1997-05-28
CN1152574A (zh) 1997-06-25
TW449595B (en) 2001-08-11
ES2159342T3 (es) 2001-10-01
HU9603237D0 (en) 1997-01-28
CZ289730B6 (cs) 2002-03-13
US5830908A (en) 1998-11-03
IL119647A (en) 1999-12-22
AR004961A1 (es) 1999-04-07
SK150096A3 (en) 1997-08-06
PT775704E (pt) 2001-09-28
BR9605646A (pt) 1998-08-18
SG44989A1 (en) 1997-12-19
NO307340B1 (no) 2000-03-20
IL119647A0 (en) 1997-02-18
UA45338C2 (uk) 2002-04-15
AU7177296A (en) 1997-05-29
NZ299780A (en) 1998-09-24
RU2181723C2 (ru) 2002-04-27
GR3036505T3 (en) 2001-11-30
HUP9603237A3 (en) 1998-12-28
HUP9603237A2 (hu) 1998-01-28
EP0775704B1 (de) 2001-06-06
CA2190700A1 (en) 1997-05-23
EP0775704A1 (de) 1997-05-28
JPH09143180A (ja) 1997-06-03
CZ342896A3 (en) 1997-06-11
MX9605741A (es) 1997-05-31
CN1086703C (zh) 2002-06-26
EE9600183A (et) 1997-06-16
DE59607040D1 (de) 2001-07-12
ATE201872T1 (de) 2001-06-15
NO964950L (no) 1997-05-23
MY132473A (en) 2007-10-31
KR970027079A (ko) 1997-06-24
ZA969753B (en) 1997-03-25

Similar Documents

Publication Publication Date Title
TR199600930A2 (tr) Kristal yapida (R)-(-)-2-{N-£4-(1,1-dioksido-3-okzo-2, 3-dihidrobenzizotiazol-2-il)-butil|- aminometil}-kroman hidroklorür.
DK0862566T3 (da) 1-(1,2-Disubstitueret piperidinyl)-4-substituerede piperazindeivater
FI943164L (fi) 2-(1-(1,3-tiatsolin-2-yyli)atsetidin-3-yyli)tiokarbapeneemijohdannaisia
IS4963A (is) Setnar 6,5-heteró-bísýklískar afleiður
SV1996000005A (es) Quinazolinonas bisustituidas en 2,8
FI961809L (fi) Uudet (R)-5-karbamoyyli-8-fluori-3-N,N-disubstituoitu-amino 3,4-dihydro-2H-1-bentsopyraanit
BR9611436A (pt) D-tartarato de (-)-cis-6(s)-fenil-5(r)-[4-(2-pirrolidin-1-iletóxi) fenil]-5,6,7,8,-tetra-hidronaftalen-2-ol
DE69606721D1 (de) 1-(5-isochinolinsulfonyl)homopiperazin hydrochlorid
NO951442D0 (no) 3,5-disubstituerte tetrahydrofuran-2-oner
NO991563L (no) N-substituerte, azaheterosykliske forbindelser
DE69618634D1 (de) 1,4-benzodioxin-derivate
NO965084D0 (no) N-[3(3-cyanopyrazol[1,5-aÅpyrimidin-7-yl)fenylÅ-N-etyl-acetamid
PT843679E (pt) Derivados da1-(piperidinil 1,2-disubstituido)-(4-imidazole fundido)-piperidina
ID21413A (id) Turunan-turunan 1,3,8,-triaza-spiro (4,5) dekan-4-on
DE59507222D1 (de) Substituierte 1,2,3,4-tetrahydro-5-nitro-pyrimidine
DE59607589D1 (de) N-aryl-1,2,4-triazolin-5-one
NO982304D0 (no) 25-Hydroksy-16-ene-26,27-bishomo-cholecalciferoler
EP0811014A4 (en) Novel bacteriocin piscicolin 126
FI962768A7 (fi) N-(2-ftaali-imidoetyyli)substituoituja transpiperidiini-2,5-dikarboksy laatteja
ATE220674T1 (de) 12h-dibenzo(d,g)(1,3)dioxocin derivate
TR199600889A2 (tr) Fungisit bilesikler (B).
NL1000001A1 (nl) Stal.
BR9510036A (pt) Derivados de 1,3,4-oxadiazina
FI960615A0 (fi) 1-(2-(substituoitu-vinyyli))-5H-2,3-bentsodiatsepiinijohdannaiset
BR9610047A (pt) 1,3,4-oxadiazolin-2-onas